🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Brian Gittleman

University of Colorado Cancer Center

ORCID: 0000-0002-2568-6286

Also affiliated with University of Colorado Denver

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer”.

Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer

Cancers(2020)10.3390/cancers12030719
N/A
0.483DataRank · unranked
24 citations

Dennis M. Simmons, Stacey M. Bagby, Sarah J. Hartman, Betelehem W. Yacob, Brian Gittleman +7 more

RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer

BMC Cancer(2020)10.1186/s12885-020-07500-1
N/A
0DataRank · unranked
30 citations

Julie Lang, Anna Capasso, Deog Joong Kim, Ely Benaim, Young Bok Lee +10 more

Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors

Molecular Cancer Therapeutics(2021)10.1158/1535-7163.mct-21-0455
N/A
0DataRank · unranked
25 citations

Todd M. Pitts, Dana Ungermannova, Christopher G. Nasveschuk, Gan Zhang, Andrew J. Phillips +15 more

Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors

(2023)10.1158/1535-7163.c.6543273.v1
N/A
0DataRank · unranked
0 citations

Todd M. Pitts, Dana Ungermannova, Christopher G. Nasveschuk, Gan Zhang, Andrew J. K. Phillips +15 more

Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors

(2023)10.1158/1535-7163.c.6543273
N/A
0DataRank · unranked
0 citations

Todd M. Pitts, Dana Ungermannova, Christopher G. Nasveschuk, Gan Zhang, Andrew J. K. Phillips +15 more